TeraRecon Achieves #1 Advanced Visualization Market Share – Extends Technology Reach with Broad PACS Distribution and Integration
Chicago, IL, Nov. 26, 2018 (GLOBE NEWSWIRE) -- November 26th, 2018 – Chicago, IL: Advanced visualization and artificial intelligence (AI) technology provider, TeraRecon, today announced it has achieved #1 market share in radiology advanced visualization as measured and reported by the prestigious and unbiased HIMSS Analytics Logic™ database. Adding to this momentum, TeraRecon has just extended the reach of its technology with an unprecedented 4 new deep integrations that bring TeraRecon iNtuition technology into the main display ports of 5 market share leading PACS companies. Additionally, 3 of these new iNtuitionTM integrations include full End-to-End AI™ capabilities where the Northstar AI Explorer™ and EnvoyAI™ platform are natively and seamlessly included. Collectively, the current market share plus the newly expanded partnerships result in TeraRecon offering their award-winning advanced visualization and artificial intelligence solutions through distribution channels that cover more than 80% of the radiology marketplace. TeraRecon and EnvoyAI solutions and integrations are on display in the TeraRecon booth, the Advanced Visualization Showcase, the Machine Learning Showcase, as well as the 6 PACS partner booths during the Radiology Society of North America (RSNA 2018) Annual Meeting in Chicago, Illinois.
“As customer engagement and the number of implementations have increased, we’ve received consistent feedback that AI should be inside the physician’s PACS reading workflow, and that physicians require ways to experiment and interact with AI before committing results to the permanent archive. Northstar* will allow the user to explore the capabilities of each algorithm and accept, adjust, or reject the findings which keeps the physician in control. You can even interact with multiple AI machines simultaneously and create fully-automatic AI Explorer workflows that present the best candidate findings from each algorithm, according to physicians’ personal preferences.” said TeraRecon Chief Executive Officer, Jeff Sorenson. He continued, “The rapid pace and wide adoption of our new AI and advanced visualization tools by PACS companies is unprecedented in our company’s history and provides proof-positive that TeraRecon and EnvoyAI are the first, best and only way to responsibly put AI into the radiologists’ workflow today.”
The combined solution delivers a complete AI strategy offering game-changing interactive capabilities and simple workflow integration with one contract, one platform to interact with, and one simple integration to any number of PACS systems. Explore the new end-to-end AI workflow by visiting TeraRecon (booth #8113) and EnvoyAI (kiosk #7367A) at the Radiology Society of North America (RSNA) Annual Meeting in Chicago, Illinois from November 25th-November 29th, 2018.
About TeraRecon: (www.terarecon.com) TeraRecon is a leader in advanced visualization, image viewing, and post-processing. Our flagship product, iNtuition, is the market share leader for radiology advanced visualization solutions. We are committed to redefining advanced visualization by leveraging artificial intelligence, and to improving radiology workflow through personalized automation features that increase efficiency. *Northstar is currently in development. Not available for diagnostic use.
About EnvoyAI: (www.envoyai.com) EnvoyAI is committed to delivering premium artificial intelligence innovations to empower the physician workflow. By intersecting sophisticated solutions with simple implementation, EnvoyAI is enabling the broad exploration and pragmatic application of artificial intelligence in healthcare.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Biome Grow receives new consumer sales amendment from Health Canada for its Nova Scotia brand, Highland Grow17.12.2018 14:00 | Pressemelding
Sales amendment granted for Highland Grow—Amendment to License Significantly Increases Product Availability for Medical and Adult Consumer-Use Markets TORONTO, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Biome Grow Inc. (“Biome” or the “Company”) (CSE: BIO) (Frankfurt: 6OTA) (OTC: ORTFF) is pleased to announce its Nova Scotia-based subsidiary, Highland Grow Inc. (“Highland Grow”), has received its sales authorization via an amendment to its existing license from Health Canada under the Cannabis Act. This authorization will allow Highland Grow to sell cannabis products to end consumers through appropriate medical and recreational cannabis channels, dramatically increasing product availability. The sales authorization will position Biome Grow to serve the rapidly growing domestic and international cannabis markets. "Biome Grow has been steadfast in its focus on a regional business strategy and building provincial brands that can serve the unique requirements of its local cannabis consumers. This n
Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis17.12.2018 13:30 | Pressemelding
DUBLIN, Ireland and CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Alkermes plc (Nasdaq: ALKS) and Biogen Inc. (Nasdaq: BIIB) today announced that Alkermes has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for diroximel fumarate (BIIB098), a novel oral fumarate in development for the treatment of relapsing forms of multiple sclerosis (MS). Alkermes is seeking approval of diroximel fumarate under the 505(b)(2) regulatory pathway, and the NDA submission includes data from EVOLVE-1, a Phase 3 pivotal trial that evaluated long-term safety in relapsing-remitting MS (RRMS) with approximately 700 patients dosed with diroximel fumarate. If approved, Biogen intends to market diroximel fumarate under the brand name VUMERITY™. This name has been conditionally accepted by the FDA and will be confirmed upon approval. “Diroximel fumarate was designed to provide patients with relapsing forms of multiple sclerosis a novel oral fumarate with a differentiated
SoftServe Documentary Receives “The Best Corporate Media of Ukraine 2018” Award17.12.2018 13:00 | Pressemelding
25th anniversary documentary takes prize in “The Best Corporate Movie” category AUSTIN, Texas, Dec. 17, 2018 (GLOBE NEWSWIRE) -- SoftServe, a leading digital authority and consulting company, announces the Ukrainian Association of Corporate Media, a public organization uniting professionals in the field of marketing, PR, journalism, and advertising, recognized SoftServe in its annual competition – “The Best Corporate Media of Ukraine 2018.” SoftServe’s 25th anniversary documentary took second place in the “The Best Corporate Movie Category.” The documentary honors the company’s 25th anniversary with an inside look at how SoftServe evolved over the past quarter century to become a leading digital authority. In the documentary, SoftServe’s founders and leadership share their inspiring stories and highlight the company’s achievements over the years. “It is a great honor to receive this recognition from the Ukrainian Association of Corporate Media for our 25th anniversary documentary,” sai
Bombardier to supply a further 20 FLEXITY trams to Karlsruhe17.12.2018 10:00 | Pressemelding
Albtal-Verkehrs-Gesellschaft expands its fleet to 62 trams The dual-system vehicles operate on both the tram network and regional railway network BERLIN, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Global mobility solution provider Bombardier Transportation received a call-off order from Albtal-Verkehrs-Gesellschaft mbH (AVG), the transport company of the Alb valley region in southwest Germany, for the delivery of 20 further dual-system BOMBARDIER FLEXITY trams. This third order is based on a framework agreement for a total of 75 vehicles from 2009. The order is valued at approximately 87 million euro ($98 million US). The vehicles will be delivered between May 2020 and March 2021. "Striving to provide attractive local transport services, we have decided to order 20 additional dual-system vehicles from Bombardier Transportation. This will allow us to purposefully enlarge our vehicle fleet offering high-quality standards to our passengers," said Dr. Alexander Pischon, CEO of Albtal-Verkehrs-Gesel
DalCor Announces Completion of Patient Enrollment in dal-GenE, the First Phase 3 Precision Medicine Cardiovascular Outcomes Trial in Coronary Heart Disease17.12.2018 09:00 | Pressemelding
LONDON and MONTREAL, Dec. 17, 2018 (GLOBE NEWSWIRE) -- DalCor today announced the completion of patient enrollment in the dal-GenE study, the first Phase 3 precision medicine cardiovascular outcomes trial in coronary heart disease. The dal-GenE study is evaluating the efficacy of the CETP inhibitor dalcetrapib to reduce clinical cardiovascular events in patients with the AA ADCY9 genotype who have had a recent acute coronary syndrome (ACS). The study has enrolled over 6,000 patients and is being conducted in 680 sites in 32 countries. “The accelerated enrollment of patients in the dal-GenE study reflects the scientific enthusiasm and commitment among the medical community to bring the right medicine to the right patient,” said Dr. Jean-Claude Tardif from the Montreal Heart Institute. “ADCY9 genetic testing to identify the appropriate patients for treatment with dalcetrapib has the potential to provide a genetically targeted therapy to improve clinical outcomes. This approach could pave
Compuware Announces Day One Support for IBM CICS Transaction Server for z/OS V5.514.12.2018 18:02 | Pressemelding